Abstract 590: Enhancing effect of resveratrol on the antileukemic effects of arsenic trioxide.

Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Arsenic trioxide (As2O3) has been approved by the FDA for the treatment of APL, in which it has major clinical activity. However, the requirement of high doses to generate antileukemic effects has been a limitation for As2O3‘s potential use in other subtypes of AML. Given As2O3‘s potent antileukemic properties in vitro, approaches to enhance its effects are of clinical and translational relevance. Resveratrol (RSV), a phytoalexin found naturally in grapes and other plants, has wide-ranging health benefits, and in leukemias, has been shown to induce apoptosis and act synergistically with other agents. In studies to examine the influence of RSV on As2O3‘s antileukemic effects, we found that RSV enhances As2O3-induced cell death in KT1 cells as shown by flow cytometric and MTT analyses to assess apoptosis and cell viability. Our studies demonstrate that combined As2O3 and RSV treatment significantly reduces leukemic progenitor colony formation in a dose dependent manner by K562, KT1, and U937 cell lines. It also results in enhanced suppressessive effects on primary leukemic progenitors from patients with myeloid leukemias. Altogether, our results suggest that use of RSV may provide an approach to enhance the antileukemic effects of As2O3 treatment by potentiating the effects of lower As2O3 doses. Citation Format: Edward J. Wu, Dennis J. Goussetis, Leonidas C. Platanias. Enhancing effect of resveratrol on the antileukemic effects of arsenic trioxide. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 590. doi:10.1158/1538-7445.AM2013-590